These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 35707347)

  • 1. Research Progress on RET Fusion in Non-Small-Cell Lung Cancer.
    Zhao L; Mei Q; Yu Y; Wang N; Zhang D; Liao D; Zuo J; Xie H; Jia Y; Kong F
    Front Oncol; 2022; 12():894214. PubMed ID: 35707347
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An overview of the role of selpercatinib and pralsetinib in RET-fusion-positive non-small cell lung cancer (NSCLC).
    Nguyen VQ; Geirnaert M
    J Oncol Pharm Pract; 2023 Mar; 29(2):450-456. PubMed ID: 36572992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 4. Pralsetinib: A Review in Advanced RET Fusion-Positive NSCLC.
    Syed YY
    Drugs; 2022 May; 82(7):811-816. PubMed ID: 35587858
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Case report: First evidence of impressive efficacy of modulated dose selpercatinib in a young Caucasian with ANK3-RET fusion-positive NSCLC.
    De Carlo E; Bertoli E; Schiappacassi M; Stanzione B; Del Conte A; Doliana R; Spina M; Bearz A
    Front Oncol; 2024; 14():1307458. PubMed ID: 38420011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. LIBRETTO-431: Confirming the Superiority of Selpercatinib to Chemotherapy and the Lack of Efficacy of Immune Checkpoint Inhibitors in Advanced
    Lee ATM; Ou SI
    Lung Cancer (Auckl); 2024; 15():75-80. PubMed ID: 38807655
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted therapy of RET fusion-positive non-small cell lung cancer.
    Shen Z; Qiu B; Li L; Yang B; Li G
    Front Oncol; 2022; 12():1033484. PubMed ID: 36582799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pralsetinib for the treatment of a
    Meng Y; Li L; Wang H; Chen X; Yue Y; Wang M; Meng L; Li B; Li X
    Ann Transl Med; 2022 Apr; 10(8):496. PubMed ID: 35571397
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
    Sun F; McCoach CE
    Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Metastatic Pulmonary Sarcomatoid Carcinoma Patient Harboring
    Qin H; Wan Y; Dong Y; Sun Q
    Cancer Manag Res; 2023; 15():765-769. PubMed ID: 37525669
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.
    Ke JY; Huang S; Jing ZT; Duan MC
    Invest New Drugs; 2023 Oct; 41(5):768-776. PubMed ID: 37603207
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Case report: Recurrent lung infections following treatment with pralsetinib for an elderly patient with
    An L; Chen P; Wang J; Qin X; Liu T; Gao Y; Wang P; Zhang D; Fang X; Zhang Z
    Front Oncol; 2022; 12():1024365. PubMed ID: 36568233
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pralsetinib: Treatment of metastatic RET fusion-positive non-small cell lung cancer.
    Nguyen L; Monestime S
    Am J Health Syst Pharm; 2022 Mar; 79(7):527-533. PubMed ID: 34864862
    [TBL] [Abstract][Full Text] [Related]  

  • 14. RET Inhibitors in Non-Small-Cell Lung Cancer.
    Cascetta P; Sforza V; Manzo A; Carillio G; Palumbo G; Esposito G; Montanino A; Costanzo R; Sandomenico C; De Cecio R; Piccirillo MC; La Manna C; Totaro G; Muto P; Picone C; Bianco R; Normanno N; Morabito A
    Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage
    Goldman JW; Sholl LM; Dacic S; Fishbein MC; Murciano-Goroff YR; Rajaram R; Szymczak S; Szpurka AM; Chao BH; Drilon A
    Front Oncol; 2023; 13():1178313. PubMed ID: 37274265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Small bowel edema and lymphocytic duodenitis as severe reversible gastrointestinal toxicity of selpercatinib in
    Scattolin D; Scagliori E; Scapinello A; Fantin A; Guarneri V; Pasello G
    Front Oncol; 2023; 13():1201599. PubMed ID: 37492479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Salvage Therapy With Selpercatinib for
    d'Arienzo PD; Cunningham N; O'Sullivan H; Grieco C; Patel V; Popat S
    JTO Clin Res Rep; 2023 Dec; 4(12):100581. PubMed ID: 38034820
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Treatment Status of Patients in NSCLC With RET Fusion Under the Prelude of Selective RET-TKI Application in China: A Multicenter Retrospective Research.
    Meng Y; Yang Y; Fang Y; Lin X; Xie X; Deng H; Wu J; Zhou M; Sun N; Xie Z; Liu M; Ouyang M; Qin Y; Su C; Zhou C
    Front Oncol; 2022; 12():864367. PubMed ID: 35692799
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
    Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
    J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in the treatment of RET-fusion-positive lung cancer.
    Pall G; Gautschi O
    Lung Cancer; 2021 Jun; 156():136-139. PubMed ID: 33933276
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.